Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19: Individual daily data

Michaël Hardy; Isabelle Michaux; Sarah Lessire; Jonathan Douxfils; Jean-Michel Dogné; Marion Bareille; Geoffrey Horlait; Pierre Bulpa; Celine Chapelle; Silvy Laporte; Sophie Testa; Hugues Jacqmin; Thomas Lecompte; Alain Dive; François Mullier

doi:10.1016/j.dib.2020.106519

Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19: Individual daily data

Michaël Hardy, Isabelle Michaux, Sarah Lessire, Jonathan Douxfils, Jean-Michel Dogné, Marion Bareille, Geoffrey Horlait, Pierre Bulpa, Celine Chapelle, Silvy Laporte, Sophie Testa, Hugues Jacqmin, Thomas Lecompte, Alain Dive, François Mullier

Universite de Namur

Résultats de recherche: Contribution à un journal/une revue › Article › Revue par des pairs

47 Téléchargements (Pure)

Résumé

This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.

langue originale	Anglais
Numéro d'article	106519
Pages (de - à)	106519
Nombre de pages	26
journal	Data in Brief
Volume	33
Date de mise en ligne précoce	2020
Les DOIs	https://doi.org/10.1016/j.dib.2020.106519
Etat de la publication	Publié - déc. 2020

Accès au document

10.1016/j.dib.2020.106519

2020_HardyMEtal_articleÉpreuve, 1,31 MB

Autres fichiers et liens

Lien vers la publication sur Scopus

The COVILAB project : Clinical laboratory investigations related to COVID-19
Douxfils, J., Dogne, J., FAVRESSE, J., Tre-Hardy, M., Mullier, F., Haguet, H., Hardy, M., Melchionda, S., BOUVY, C., Morimont, L., Gillot, C., Djokoto, H., Alpan, L., Devel, P., Modaffari, E. & Maloteau, V.
13/03/20 → …
Projet: Recherche

Contient cette citation

Hardy, M., Michaux, I., Lessire, S., Douxfils, J., Dogné, J.-M., Bareille, M., Horlait, G., Bulpa, P., Chapelle, C., Laporte, S., Testa, S., Jacqmin, H., Lecompte, T., Dive, A., & Mullier, F. (2020). Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19: Individual daily data. Data in Brief, 33, 106519. Article 106519. https://doi.org/10.1016/j.dib.2020.106519

@article{968f3fef45a44fd2a6f07aae144c0f41,

title = "Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19: Individual daily data",

abstract = "This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.",

keywords = "covid-19, Intensive Care Units, thrombin generation, Fibrinolysis, D-dimers, hemostasis plasma proteins, COVID-19, Thrombin generation, Hemostasis plasma proteins, Thrombosis, Intensive care unit",

author = "Micha{\"e}l Hardy and Isabelle Michaux and Sarah Lessire and Jonathan Douxfils and Jean-Michel Dogn{\'e} and Marion Bareille and Geoffrey Horlait and Pierre Bulpa and Celine Chapelle and Silvy Laporte and Sophie Testa and Hugues Jacqmin and Thomas Lecompte and Alain Dive and Fran{\c c}ois Mullier",

note = "Funding Information: This work was supported by the Belgian Fonds National de la Recherche Scientifique : {\textquoteleft}Anticoagulation fibrinolysis COVID19{\textquoteright} (reference: 40002796). Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = dec,

doi = "10.1016/j.dib.2020.106519",

language = "English",

volume = "33",

pages = "106519",

journal = "Data in Brief",

issn = "2352-3409",

publisher = "Elsevier",

}

TY - JOUR

T1 - Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19

T2 - Individual daily data

AU - Hardy, Michaël

AU - Michaux, Isabelle

AU - Lessire, Sarah

AU - Douxfils, Jonathan

AU - Dogné, Jean-Michel

AU - Bareille, Marion

AU - Horlait, Geoffrey

AU - Bulpa, Pierre

AU - Chapelle, Celine

AU - Laporte, Silvy

AU - Testa, Sophie

AU - Jacqmin, Hugues

AU - Lecompte, Thomas

AU - Dive, Alain

AU - Mullier, François

N1 - Funding Information: This work was supported by the Belgian Fonds National de la Recherche Scientifique : ‘Anticoagulation fibrinolysis COVID19’ (reference: 40002796). Publisher Copyright: © 2020 The Authors

PY - 2020/12

Y1 - 2020/12

N2 - This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.

AB - This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.

KW - covid-19

KW - Intensive Care Units

KW - thrombin generation

KW - Fibrinolysis

KW - D-dimers

KW - hemostasis plasma proteins

KW - COVID-19

KW - Thrombin generation

KW - Hemostasis plasma proteins

KW - Thrombosis

KW - Intensive care unit

UR - http://www.scopus.com/inward/record.url?scp=85096654587&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2020.106519

DO - 10.1016/j.dib.2020.106519

M3 - Article

C2 - 33200086

SN - 2352-3409

VL - 33

SP - 106519

JO - Data in Brief

JF - Data in Brief

M1 - 106519

ER -

Prothrombotic Hemostasis Disturbances in Patients with Severe COVID-19: Individual daily data

Résumé

Accès au document

Autres fichiers et liens

Empreinte digitale

Projets

The COVILAB project : Clinical laboratory investigations related to COVID-19

Contient cette citation